Karolinska Development appoints Benjamin Nordin as Investor Relations Director
(Thomson Reuters ONE) -
Stockholm - 22 February 2011 - Karolinska Development AB today announced that
Benjamin Nordin has been appointed Investor Relations Director. In this new
role, Benjamin will be responsible for both Business Analysis and Communication.
"Benjamin fits very well in this new role. As Head of Business Analysis,
Benjamin has a deep and broad understanding of Karolinska Development and its
portfolio companies. He also has a background as an equity analyst, which is an
excellent experience in a situation where the company is planning an IPO.", says
Torbjørn Bjerke, CEO of Karolinska Development.
Benjamin will be responsible for Communication and Investor Relations but will
also retain his former responsibility for Business Analysis. As a part of this
change, Benjamin will be part of Karolinska Development's management team.
Benjamin is M.Sc. in molecular biology and he has a degree from Uppsala Graduate
School in Biomedical Research. Prior to Karolinska Development, he was head of
the healthcare analyst team at Kaupthing Bank.
For further information, please contact:
Torbjørn Bjerke, CEO
Karolinska Development AB
Phone: +46 (0)72 744 41 23
torbjorn.bjerke(at)karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class research into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP these to
the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out licensing of
products. This will result in upfront payments, milestone payments and
royalties.
An exclusive deal flow agreement with Karolinska Innovations, along with
cooperation agreements with other leading Nordic universities, ensures the first
right of refusal to a continuous flow of innovations.
Karolinska Developments flexible exit strategy enables projects to be exited at
whichever stage of development offers the greatest return on investment, usually
after Phase II clinical trials have indicated the desired pharmaceutical effect
on patients - this being an important value enhancing step.
Today, the portfolio consists of over 40 projects at various stages, from
concept development to Phase II clinical trials, twelve projects are in clinical
trials with six in Phase II. The portfolio is particularly strong in the areas
of cancer, dermatology, inflammation, cardiovascular disease, women's health and
diseases that affect the central nervous system. www.karolinskadevelopment.com
Press release as PDF:
http://hugin.info/143071/R/1491112/426729.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1491112]
Unternehmensinformation / Kurzprofil:
Datum: 22.02.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 51756
Anzahl Zeichen: 3702
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development appoints Benjamin Nordin as Investor Relations Director"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
